Search results for "uva"

showing 10 items of 2916 documents

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.

2013

This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent. In different animal models of neurotoxicity and neurodegenerative diseases, we demonstrated its neuroprotecting activity. By the use of immunohistochemical methods and Western blot analysis, as well as some selected behavioral tests, the new mechanisms of mildronate have been demonstrated: a regulatory effect on mitochondrial processes and on the expression of nerve cell proteins, which are involved in cell survival, functioning, and inflammation processes. Particular attention is paid to the capability of mildronate to stimulate…

Neurotoxicity SyndromeNerve Tissue ProteinsMitochondrionNeuroprotectionMiceAdjuvants ImmunologicNeuritismedicineAnimalsHumansLearningNeuroinflammationNeuronsbusiness.industryNeurogenesisNeurodegenerationNeurotoxicityParkinson DiseaseGeneral Medicinemedicine.diseaseMitochondriaNerve RegenerationRatsDisease Models AnimalNeuroprotective AgentsSynaptic plasticityNeurotoxicity SyndromesbusinessNeuroscienceMethylhydrazinesMedicina (Kaunas, Lithuania)
researchProduct

Hyperspectral Imaging for Non-invasive Diagnostics of Melanocytic Lesions

2022

Malignant melanoma poses a clinical diagnostic problem, since a large number of benign lesions are excised to find a single melanoma. This study assessed the accuracy of a novel non-invasive diagnostic technology, hyperspectral imaging, for melanoma detection. Lesions were imaged prior to excision and histopathological analysis. A deep neural network algorithm was trained twice to distinguish between histopathologically verified malignant and benign melanocytic lesions and to classify the separate subgroups. Furthermore, 2 different approaches were used: a majority vote classification and a pixel-wise classification. The study included 325 lesions from 285 patients. Of these, 74 were invasi…

Nevus PigmentedSkin Neoplasmshyperspectral imagingmalignant melanomaHyperspectral ImagingDermatologyGeneral Medicinediagnostiikka3121 Internal medicineSensitivity and Specificityihosyöpämachine learningkoneoppiminenHumansmelanoomaMelanomahyperspektrikuvantaminennon-invasive diagnostic
researchProduct

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

2021

Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. W…

Non-Hormonal Preparationsmedicine.medical_specialtyChronic conditionmedicine.drug_classmedicine.medical_treatmentUrinary systemVaginal DiseasesUrinary incontinenceVulvovaginal atrophyGeneral Biochemistry Genetics and Molecular BiologyVulvovaginal Atrophy03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineHumansEndocrine system030212 general & internal medicineExpert Testimony030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyEstrogensPostmenopauseTopical EstrogensAdministration IntravaginalEstrogenPractice Guidelines as TopicQuality of LifeFemaleVulvar DiseasesAtrophymedicine.symptombusinessAdjuvantMaturitas
researchProduct

Una nuova politica di sviluppo regionale nell'Unione Europea e nell'OCSE agli inizi del Ventunesimo Secolo

2010

Le politiche di sviluppo economico regionale nell’ambito europeo e dell’OCSE degli anni settanta furono indirizzate alla correzione delle disparità economiche (tassi di crescita del Pil e del reddito disequilibrati) tecniche, di redistribuzione delle opportunità tra regioni e di insufficiente dotazioni di risorse (umane, finanziarie, tecniche e infrastrutturali) ed impiantate sui massicce assistenze finanziarie (per infrastrutture e per sviluppare i servizi pubblici) alle regioni più povere, nelle quali creare ex‐nihilo dei tecnopoli ed artificialmente poli economici di sviluppo a livello regionale ed infine tentare di mantenere in vita settori industriali in declino per proteggere l’impieg…

Nuona politica regionaleNuova politica regionale europeaNuva Politica dell'OCSEPolitiche multilivelloSettore SECS-P/06 - Economia Applicata
researchProduct

Aikuisuus nuorten kokemana : nuorten kokemuksia aikuisten arjesta ja mielikuvia omasta tulevaisuudesta aikuisena

2015

Jokinen, Veera. 2015. Aikuisuus nuorten kokemana. Nuorten kokemuksia aikuisten arjesta ja mielikuvia omasta tulevaisuudesta aikuisena. Kasvatustieteen pro gradu- tutkielma. Jyväskylän yliopisto. Opettajankoulutuslaitos. Tämän tutkimuksen tarkoituksena oli tutkia nuorten kokemuksellista suhdetta aikuisuuteen. Tavoitteena oli ymmärtää, miten nuoret kokevat heitä ympäröivien aikuisten arjen ja elämän, sekä millaisia tulevaisuuskuvia nuorilla on omasta aikuisuudestaan. Tutkimuksen tavoitteena oli lisätä ymmärrystä nuorten kokemuksista ohjauksen kehittämiseksi. Tutkimus toteutettiin aineistolähtöisesti fenomenologisen metodin ohjaamana. Kohdejoukkona toimivat 9.-luokkalaiset nuoret. Aineisto ker…

Nuoruusaikuisuusnuorettulevaisuuskuvakokemuksetohjaus (neuvonta ja opastus)arkiohjaustulevaisuuskokemus
researchProduct

Differentiating Malignant from Benign Pigmented or Non-Pigmented Skin Tumours—A Pilot Study on 3D Hyperspectral Imaging of Complex Skin Surfaces and …

2022

Several optical imaging techniques have been developed to ease the burden of skin cancer disease on our health care system. Hyperspectral images can be used to identify biological tissues by their diffuse reflected spectra. In this second part of a three-phase pilot study, we used a novel hand-held SICSURFIS Spectral Imager with an adaptable field of view and target-wise selectable wavelength channels to provide detailed spectral and spatial data for lesions on complex surfaces. The hyperspectral images (33 wavelengths, 477–891 nm) provided photometric data through individually controlled illumination modules, enabling convolutional networks to utilise spectral, spatial, and skin-surface mo…

OPTICAL COHERENCE TOMOGRAPHYskin cancerhyperspectral imagingskin imagingphotometric stereoMELANOMAGeneral Medicineneuroverkotdiagnostiikkabiomedical optical imagingnon-invasive imagingDIAGNOSISCANCERoptical modellingkarsinoomatCLASSIFICATIONihosyöpäkoneoppiminenSDG 3 - Good Health and Well-beingbiomedical optical imaging; convolutional neural networks; hyperspectral imaging; non-invasive imaging; optical modelling; photometric stereo; skin cancer; skin imaging3121 General medicine internal medicine and other clinical medicineconvolutional neural networks/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmelanoomahyperspektrikuvantaminen
researchProduct

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.

2002

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% (0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng…

OlanzapineAdultMaleTime FactorsCombination therapyFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsmedicineHumansPharmacology (medical)Drug InteractionsProspective Studiesmedicine.diagnostic_testbusiness.industryDopamine antagonistPirenzepineDrug interactionMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringChemotherapy AdjuvantFluvoxamineOlanzapineChronic DiseaseSchizophreniaFemalebusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugFollow-Up StudiesJournal of clinical psychopharmacology
researchProduct

CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective r…

2015

4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...

Oncology0303 health sciencesCancer Researchmedicine.medical_specialtyendocrine system diseasesAdjuvant chemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinemedicineAdjuvant therapyErlotinibbusiness030304 developmental biologymedicine.drugJournal of Clinical Oncology
researchProduct

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant …

2020

Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients. Several factors, particularly morphological criteria combined with dynamic parameters, known before LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies. Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the International Liver Transplantation Society Consensus …

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularConsensusmedicine.medical_treatmentConsensus Development Conferences as TopicMEDLINE030230 surgeryLiver transplantationMedical OncologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientGrading (tumors)Societies MedicalPostoperative CareTransplantationbusiness.industryLiver NeoplasmsConsensus conferenceImmunosuppressionChemoradiotherapy Adjuvantmedicine.diseasePrognosisUnited StatesLiver TransplantationQuality of evidenceEuropeTreatment OutcomeHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct